Zymeworks Inc. (NYSE/TSX: ZYME) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks’ second candidate, ZW49, is a bispecific antibody-drug conjugate (ADC) and is expected to be the subject of an Investigational New Drug (IND) filing in 2018. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global pharmaceutical companies: Merck, Eli Lilly, Celgene, GSK, Daiichi Sankyo, and Janssen.
Home > Organizations > Zymeworks Inc.
Zymeworks Inc.
Showcase Employer

Active Jobs
Vancouver, BC
Contracts Manager - Zymeworks Inc.
Posted: June 23, 2022
Closes: July 23, 2022
Full-Time
Vancouver, BC
Director, Legal - Zymeworks Inc.
Posted: June 23, 2022
Closes: July 23, 2022
Full-Time
Vancouver, BC
Senior Statistical Programmer - Zymeworks Inc.
Posted: June 23, 2022
Closes: July 23, 2022
Full-Time